White House says popular weight-loss drug Ozempic subject to Medicare talks
Analysts at Argus Research say the stock is now trading at 22 times its estimated 2025 earnings.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
